company background image
JAN logo

JanOne NasdaqCM:JAN Stock Report

Last Price

US$2.52

Market Cap

US$12.5m

7D

-2.2%

1Y

109.1%

Updated

27 Mar, 2024

Data

Company Financials

JAN Stock Overview

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction.

JAN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance1/6
Financial Health4/6
Dividends0/6

JanOne Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for JanOne
Historical stock prices
Current Share PriceUS$2.52
52 Week HighUS$3.20
52 Week LowUS$0.22
Beta2.18
1 Month Change135.73%
3 Month Change351.58%
1 Year Change109.15%
3 Year Change-70.04%
5 Year Change1.91%
Change since IPO-98.64%

Recent News & Updates

JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry

Feb 14
JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry

Recent updates

JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry

Feb 14
JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry

Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now

Oct 03
Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now

JanOne to acquire Soin Therapeutics

Sep 16

Does JanOne (NASDAQ:JAN) Have A Healthy Balance Sheet?

Aug 17
Does JanOne (NASDAQ:JAN) Have A Healthy Balance Sheet?

Health Check: How Prudently Does JanOne (NASDAQ:JAN) Use Debt?

Mar 21
Health Check: How Prudently Does JanOne (NASDAQ:JAN) Use Debt?

Is JanOne (NASDAQ:JAN) Using Debt In A Risky Way?

Nov 19
Is JanOne (NASDAQ:JAN) Using Debt In A Risky Way?

JanOne adds Nicholas Goeders to scientific advisory board

Jun 15

JanOne advances toward initiation of mid-stage peripheral artery disease trial

Jun 08

JanOne under pressure on pricing $6M stock offering

Jan 29

Shareholder Returns

JANUS Commercial ServicesUS Market
7D-2.2%2.3%0.4%
1Y109.1%36.5%28.8%

Return vs Industry: JAN exceeded the US Commercial Services industry which returned 35.6% over the past year.

Return vs Market: JAN exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is JAN's price volatile compared to industry and market?
JAN volatility
JAN Average Weekly Movement26.5%
Commercial Services Industry Average Movement6.8%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: JAN's share price has been volatile over the past 3 months.

Volatility Over Time: JAN's weekly volatility has increased from 20% to 26% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1976203Tony Isaachttps://www.janone.com

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company’s lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain.

JanOne Inc. Fundamentals Summary

How do JanOne's earnings and revenue compare to its market cap?
JAN fundamental statistics
Market capUS$12.50m
Earnings (TTM)US$155.00k
Revenue (TTM)US$39.61m

80.7x

P/E Ratio

0.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
JAN income statement (TTM)
RevenueUS$39.61m
Cost of RevenueUS$31.99m
Gross ProfitUS$7.62m
Other ExpensesUS$7.46m
EarningsUS$155.00k

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.031
Gross Margin19.23%
Net Profit Margin0.39%
Debt/Equity Ratio0%

How did JAN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.